Incidence of Liver Toxicity Associated with the Use of Flutamide in Prostate Cancer Patients

    José‐Luis Gomez, André Dupont, Lionel Cusan, M. Tremblay, Raul Suburu, Martin Lemay, Fernand Labrie
    Image of study
    TLDR Flutamide rarely causes liver toxicity in prostate cancer patients.
    In a study of 1,091 prostate cancer patients treated with flutamide and a LHRH agonist, only four patients (0.36%) experienced significant liver toxicity, with two (0.18%) developing clinical liver disease. The toxicity resolved upon discontinuation of flutamide. The majority of patients had no or only mild and transient liver enzyme elevations. The study concluded that flutamide-induced liver toxicity is rare and recommended monitoring liver function at the start of treatment and after 2 and 4 weeks to quickly identify and manage any potential liver injury.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 21 results

    Similar Research

    5 / 1000+ results